-
Teva names two new executives
JERUSALEM — Teva Pharmaceutical Industries has named Carlo De Notaristefani as president and CEO of global operations and Aharon "Arik" Yaari as EVP community and institutional affairs, the Israeli drug maker said Thursday.
The company said De Notaristefani and Yaari would report directly to Teva president and CEO Jeremy Levin.
-
FDA approves Watson asthma generic
PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug designed to treat asthma in children.
Watson Pharmaceuticals announced Wednesday the approval of budesonide inhalation suspension in the 0.25-mg/2-mL and 0.5-mg/2-mL strengths. The drug is used to control and prevent asthma symptoms in children ages 12 months to 8 years.
The drug is a generic version of AstraZeneca's Pulmicort Respules, which had sales of $1.1 billion during the 12-month period ended in May.